Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$61.40
+2.9%
$57.92
$30.82
$68.73
$2.13B0.77395,413 shs356,331 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.00%+0.40%+1.15%+25.84%+17.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.2492 of 5 stars
4.51.00.00.03.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.09
Buy$98.3060.10% Upside

Current Analyst Ratings Breakdown

Latest SRES, IRON, KDNC, and PXC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$85.00 ➝ $90.00
7/21/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
7/21/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$86.00
7/3/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$85.00
7/3/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$118.00
6/17/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$118.00
6/16/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$90.00
6/11/2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageStrong-Buy$89.00
(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$14.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$109.36M-$4.47N/AN/AN/AN/A-26.60%-24.58%11/11/2025 (Estimated)

Latest SRES, IRON, KDNC, and PXC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.17-$1.58-$0.41-$1.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.05
32.11
32.11

Institutional Ownership

CompanyInstitutional Ownership
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%

Insider Ownership

CompanyInsider Ownership
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3034.77 million33.50 millionNot Optionable

Recent News About These Companies

Walleye Capital LLC Trims Position in Disc Medicine, Inc. $IRON
Disc Medicine (IRON) Receives a Buy from TD Cowen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$61.40 +1.75 (+2.93%)
Closing price 04:00 PM Eastern
Extended Trading
$61.41 +0.01 (+0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.